Biocon approves plan to raise $527 millionRecently, Biocon Biologics had inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US.
Last Updated IST
Biocon logo
Credit: DH File Photo
Biopharma firm Biocon said on Wednesday it will raise funds worth up to $527.3 million) via issue of securities, which may include debt and selling shares to institutional investors.
Recently, Biocon Biologics had inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US.